대한임상독성학회지 (Journal of The Korean Society of Clinical Toxicology)
- 제12권2호
- /
- Pages.92-96
- /
- 2014
- /
- 1738-1320(pISSN)
- /
- 2508-6332(eISSN)
급성신손상으로 인해 발생한 dabigatran 독성
Dabigatran Toxicity Secondary to Acute Kidney Injury
- 문형호 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 이승은 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 오동준 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 조희범 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 권기환 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 김윤진 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 김경수 (동국대학교 의과대학 동국대학교 일산병원 내과학교실) ;
- 신성준 (동국대학교 의과대학 동국대학교 일산병원 내과학교실)
- Moon, Hyoung Ho (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Lee, Seung Eun (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Oh, Dong Jun (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Jo, Hee Bum (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Kwon, Ki Hwan (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Kim, Yoon Jin (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Kim, Kyung Soo (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine) ;
- Shin, Sung Joon (Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine)
- 투고 : 2014.07.03
- 심사 : 2014.08.07
- 발행 : 2014.12.31
초록
Dabigatran is the first oral direct thrombin inhibitor approved by the US Food and Drug Administration (FDA) for prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Because dabigatran is excreted mainly by the kidneys, serum levels of dabigatran can be elevated to a supratherapeutic range in patients with renal failure, predisposing to emergent bleeding. We describe the case of a 66-year-old man taking dabigatran 150 mg twice daily for atrial fibrillation and cerebral infarction who presented with hematochezia and disseminated intravascular coagulation. Laboratory evaluation showed a hemoglobin level of 6.3 g/dL, platelets of